Novartis Presents New Multiple Sclerosis Trial Data at MSToronto2026
FROM THE WIRE · FINANCE.YAHOO.COM
Novartis (SWX:NOVN) just put multiple sclerosis front and center for investors, flagging 46 abstracts for MSToronto2026, including late breaking Phase III REMODEL data on remibrutinib and new Kesimpta pediatric results. At a share price of CHF120.02, Novartis has logged a 1-day…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishNew MS trial data and Kesimpta pediatric results support Novartis momentum, with 1-day share price up 2.42%.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Novartis presented 46 abstracts for MSToronto2026, including Phase III REMODEL data on remibrutinib.
- 02New Kesimpta pediatric results were also presented.
- 03The share price returned 2.42% in 1 day, with year-to-date return up 10.62%.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets